Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2.
Hasegawa E, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Hasegawa E, et al. Among authors: yatsuji h. Hepatol Res. 2007 Oct;37(10):793-800. doi: 10.1111/j.1872-034X.2007.00140.x. Epub 2007 Jun 25. Hepatol Res. 2007. PMID: 17593231
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Akuta N, et al. Among authors: yatsuji h. J Hepatol. 2007 Mar;46(3):403-10. doi: 10.1016/j.jhep.2006.09.019. Epub 2006 Nov 7. J Hepatol. 2007. PMID: 17126448 Clinical Trial.
Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load.
Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H. Sezaki H, et al. Among authors: yatsuji h. Hepatol Res. 2007 Oct;37(10):787-92. doi: 10.1111/j.1872-034X.2007.00132.x. Epub 2007 Jun 15. Hepatol Res. 2007. PMID: 17573943
Changes in viral loads of lamivudine-resistant mutants during entecavir therapy.
Suzuki F, Suzuki Y, Akuta N, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kobayashi M, Watahiki S, Kumada H. Suzuki F, et al. Among authors: yatsuji h. Hepatol Res. 2008;38(2):132-40. doi: 10.1111/j.1872-034X.2007.00144.x. Epub 2007 Jun 15. Hepatol Res. 2008. PMID: 17573951
Prolonged hepatitis after acute infection with genotype H hepatitis B virus.
Chihara N, Arase Y, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Watahiki S, Ikeda K, Kumada H. Chihara N, et al. Among authors: yatsuji h. Intern Med. 2007;46(22):1847-51. doi: 10.2169/internalmedicine.46.0163. Epub 2007 Nov 16. Intern Med. 2007. PMID: 18025766 Free article.
73 results